GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NEOE:ABBV) » Definitions » Loans Receivable

AbbVie (NEOE:ABBV) Loans Receivable : C$0 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is AbbVie Loans Receivable?

AbbVie's Loans Receivable for the quarter that ended in Dec. 2024 was C$0 Mil.


AbbVie Loans Receivable Historical Data

The historical data trend for AbbVie's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Loans Receivable Chart

AbbVie Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AbbVie Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AbbVie Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


AbbVie Loans Receivable Related Terms

Thank you for viewing the detailed overview of AbbVie's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie Business Description

Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).